OncoLab Diagnostics has secured the following intellectual property rights:
Cancer Diagnosis and Prognosis
A method of identifying an SCLC patient at risk of disease progression comprising determining the RNA-expression of at least one marker selected from a neuroendocrine marker and/or DLL3 in a fraction of a blood sample of said patient which blood fraction is enriched in circulating tumor cells (CTCs), wherein said at least one marker is indicative of the patient’s prognosis.
Composition and method for determination of CK19 expression
Method for quantitative determination of CK19 mRNA-positive cells in a biological sample.
Diagnostic tests for circulating tumor cells in breast, ovarian, endometrial and cervical cancer.
Method and kit for diagnosis of a cancerous disease, method for determining the reaction of a patient to the treatment for a cancerous disease medicament for the prophylaxis or treatment of a cancerous disease
Diagnostic tests for circulating tumor cells in ovarian cancer.
Diagnostic test for early detection of ovarian cancer based on RNA biomarkers and RNA/protein biomarker models.